secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2026-05-11T20:05:24+00:00
Accession:  0001193125-26-216745
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio appoints Christopher Murphy CFO ($42,917/mo) and Owen Hughes to board
--------------------------------------------------------------------------------

- Christopher Murphy appointed CFO effective May 11, 2026; previously CFO at Third Harmonic Bio and Horizon Therapeutics.
- Murphy's consulting agreement: $42,916.66 monthly fee, target bonus up to 40% of annual fees, and $1.75M RSU grant vesting over 4 years.
- Owen Hughes appointed Class I director effective May 11, 2026; receives initial grant of 11,250 RSUs vesting over 3 years.
- Murphy serves as independent contractor; severance provides 9-12 months fee continuation based on termination cause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526216745/0001193125-26-216745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526216745/anab-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer